1. Home
  2. FTHY vs EOLS Comparison

FTHY vs EOLS Comparison

Compare FTHY & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Trust High Yield Opportunities 2027 Term Fund

FTHY

First Trust High Yield Opportunities 2027 Term Fund

N/A

Current Price

$14.05

Market Cap

539.8M

Sector

Finance

ML Signal

N/A

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$5.91

Market Cap

444.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTHY
EOLS
Founded
2020
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
539.8M
444.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
FTHY
EOLS
Price
$14.05
$5.91
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$20.50
AVG Volume (30 Days)
176.7K
891.1K
Earning Date
01-01-0001
11-05-2025
Dividend Yield
10.93%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$285,823,000.00
Revenue This Year
N/A
$14.24
Revenue Next Year
N/A
$21.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
15.10
52 Week Low
$12.66
$5.71
52 Week High
$14.74
$17.12

Technical Indicators

Market Signals
Indicator
FTHY
EOLS
Relative Strength Index (RSI) 50.29 29.49
Support Level $13.98 $6.57
Resistance Level $14.15 $6.80
Average True Range (ATR) 0.09 0.27
MACD 0.01 -0.12
Stochastic Oscillator 53.63 6.23

Price Performance

Historical Comparison
FTHY
EOLS

About FTHY First Trust High Yield Opportunities 2027 Term Fund

FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: